There’s a new biotech venture capital fund on the scene, following the launch today of Cure Ventures with $350 million in capital commitments and a pledge to help start-up
Okyo Pharma has decided to delist its shares from the London Stock Exchange and list them on the Nasdaq in New York, blaming “negligible” trading that doesn’t justify the